November proved to be another productive month for psychedelic research. A variety of surveys looked at how psychedelics alter beliefs, reduce opioid use, and the effects of microdosing. A finished Phase I trial clear 5-MeO-DMT for the next step, cannabis intensifies a psychedelic experience, and psychedelics may help with Alzheimer’s.
In the Research Briefing of December 6th: 1) The methodological challenges faced in psychedelic clinical trials (and how to fix them) 2) Mystical experiences in recreational use associated with improvements in wellbeing 3) A novel 5-MeO-DMT formulation proves to be safe in Phase I trial
This is all the other psychedelic research that came out in December 2021.
In the Research Briefing of November 22nd: 1) Those who microdose report lower anxiety & depression 2) Psilocybin therapy increases cognitive and neural flexibility 3) How can psilocybin help decrease craving in alcoholism
In light of the results of Compass Pathways Phase IIb trial with COMP360, the adverse events elicited by psychedelics have become a significant talking point. In this article, we look at these results and situate them within other clinical research using psychedelics.
In the Research Briefing of November 8th: 1) To patent or not to patent psychedelics 2) Getting psychedelics to a community clinic near you 3) The influence of cannabis on psychedelic experiences
Explore the studies that have used psilocybin (in combination with therapy) to improve (treatment-resistant) depression.
October brought us 26 novel publications on psychedelics as medicine. Several studies explored the effects of low doses of LSD, others investigated the positive outcomes of ketamine, whilst some dove into the outcomes of MDMA. Some of the papers published describe interesting experiments and surveys, although many are reviews.
This is all the other psychedelic research that came out in November 2021.
In the Research Briefing of October 25th: 1) A summary of what we know about 5-MeO-DMT 2) Investigating ketamine’s chemical structure for safety and efficacy 3) Testing how LSD works in the brain by modelling the effects in a whole-brain simulation